Capromorelin for Fat Loss
Oral non-peptide ghrelin-receptor agonist; FDA-approved as a veterinary appetite stimulant.
Why Capromorelin for fat loss?
Capromorelin is a small-molecule ghrelin agonist (GHSR1a) approved by the FDA for appetite stimulation in dogs (Entyce, 2016) and cats (Elura, 2020). Human Phase 2 trials in elderly sarcopenia showed modest gains in tandem-walk and lean mass before development was halted.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Capromorelin fits this goal because its category (Performance) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Stimulates appetite
Reference dosing by bodyweight
Anchored to the most-cited research dose (3000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1870–2530 mcg |
| 60–75 kg / 132–165 lb | 2295–3105 mcg |
| 75–90 kg / 165–198 lb | 2805–3795 mcg |
| 90–105 kg / 198–231 lb | 3315–4485 mcg |
| >105 kg / >231 lb | 3825–5175 mcg |
Side effects to weigh against fat loss benefit
- Hypersalivation (in dogs/cats)
- Mild emesis
- Lethargy
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.